IZALONTAMAB

UNII:	S8YH2C9NLA
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	IZALONTAMAB
GSRS Full Record:	S8YH2C9NLA i

2559704-24-2
Anti-EGFR/HER3 Bispecific Antibody SI-B001
HER3 x EGFR SI-B001
IZALONTAMAB [USAN]
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 γ1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), disulfide with human-mouse monoclonal C225 κ-chain, dimer
Immunoglobulin G1-scFv_L-kappa dimer, anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)] and anti-[Homo sapiens ERBB3 (receptor tyrosine protein kinase erbB-3, HER3)], monoclonal antibody, tetravalent, bispecific; G1-scFv fused chain (1-702) [gamma1 heavy chain anti-EGFR (1-448) [VH (Mus musculus IGHV2-2*03 (93.8%) -(IGHD) -IGHJ3*01 (92.9%) A128>S (119), CDR-IMGT [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo sapiens IGHG1*08p (100%), G1m3,1 (CH1 I103 (201), R120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)] -10-mer bis(tetraglycyl-seryl) linker (449-458) -scFv heavy-lambda anti-ERBB3 (459-702) [VH (Homo sapiens IGHV3-7*01 (91.8%) -(IGHD) -IGHJ2*01 (100%), CDR-IMGT [8.8.11] (484-491.509-516.555-565)) (459-576) -15-mer tris(tetraglycyl-seryl) linker (577-591) -V-LAMBDA (Homo sapiens IGLV2-14*03 (93.9%) -IGLJ2*01 (83.3%) L124>V (699), CDR-IMGT [9.3.11] (617-625.643-645.682-692)) (592-702)]], (222-214')-disulfide with kappa light chain anti-EGFR (1'-214') [V-KAPPA (Mus musculus IGKV5-48*01 (95.8%) -IGKJ5*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
Izalontamab
Izalontamab [WHO-DD]
SI-B001
izalontamab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

IZALONTAMAB

Synonyms and Mappings

Resources